{
    "organizations": [],
    "uuid": "96ec54901b60f9c9fbbcea3604ae079b0df2de07",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-zogenix-completes-enrollment-in-se/brief-zogenix-completes-enrollment-in-second-zx008-phase-3-clinical-trial-in-dravet-syndrome-idUSASB0C3BK",
    "ord_in_thread": 0,
    "title": "BRIEF-Zogenix Completes Enrollment In Second ZX008 Phase 3 Clinical Trial In Dravet Syndrome",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 31 (Reuters) - Zogenix Inc:\n* ZOGENIX COMPLETES ENROLLMENT IN SECOND ZX008 PHASE 3 CLINICAL TRIAL IN DRAVET SYNDROME\n* ZOGENIX INC SAYS ‍TOP-LINE DATA ON TRACK FOR 2Q 2018 FOR SECOND PHASE 3 CLINICAL TRIAL EVALUATING ZX008​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-01T06:20:00.000+02:00",
    "crawled": "2018-02-01T14:56:43.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "zogenix",
        "inc",
        "zogenix",
        "completes",
        "enrollment",
        "second",
        "zx008",
        "phase",
        "clinical",
        "trial",
        "dravet",
        "syndrome",
        "zogenix",
        "inc",
        "say",
        "data",
        "track",
        "2q",
        "second",
        "phase",
        "clinical",
        "trial",
        "evaluating",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}